K C Oeffinger1, D A Eshelman, G E Tomlinson, G R Buchanan, B M Foster. 1. Department of Family Practice and Community Medicine, After the Cancer Experience (ACE) Young Adult Program, The University of Texas Southwestern Medical Center at Dallas, Dallas, Texas 75235-9067, USA.
Abstract
BACKGROUND: The objective of the current study was to describe a multidisciplinary transition program for following young adult survivors of childhood cancer in an adult-based ambulatory medical setting and to report the late effects with grades of toxicity diagnosed in all adult survivors followed in the program. METHODS: The study population was comprised of all young adult survivors (n = 96) of childhood cancer who were seen in the After the Cancer Experience (ACE) Young Adult Program prior to January 31, 1999. The median age of the survivors was 22.8 years (range, 17-34 years) and the median interval from the time of cancer diagnosis was 15.2 years (range, 6-25 years). Primary cancer groups included: leukemia, 33%; sarcoma, 24%; Hodgkin disease, 15%; non-Hodgkin lymphoma, 12%; Wilms' tumor, 9%; and other, 7%. Late effects were graded using the Common Toxicity Criteria, Version 2 (CTCv2), developed by the National Cancer Institute. RESULTS: Approximately 69% of the patients (66 of 96) had at least 1 late effect. Thirty-three percent of patients had a single late effect whereas 36% had >/= 2 late effects. Thirty percent of patients had a CTCv2 Grade 3 or 4 late effect. CONCLUSIONS: The current study represents an example of a successful multidisciplinary transition program in an ambulatory, adult setting for young adult survivors of childhood cancer. Late effects of cancer treatment are common in young adult survivors, with approximately 33% being moderate to severe. Further studies are needed to modify CTCv2 with the aim of developing a reliable and valid tool to assess late effects in long term survivors of childhood cancer. Copyright 2000 American Cancer Society.
BACKGROUND: The objective of the current study was to describe a multidisciplinary transition program for following young adult survivors of childhood cancer in an adult-based ambulatory medical setting and to report the late effects with grades of toxicity diagnosed in all adult survivors followed in the program. METHODS: The study population was comprised of all young adult survivors (n = 96) of childhood cancer who were seen in the After the Cancer Experience (ACE) Young Adult Program prior to January 31, 1999. The median age of the survivors was 22.8 years (range, 17-34 years) and the median interval from the time of cancer diagnosis was 15.2 years (range, 6-25 years). Primary cancer groups included: leukemia, 33%; sarcoma, 24%; Hodgkin disease, 15%; non-Hodgkin lymphoma, 12%; Wilms' tumor, 9%; and other, 7%. Late effects were graded using the Common Toxicity Criteria, Version 2 (CTCv2), developed by the National Cancer Institute. RESULTS: Approximately 69% of the patients (66 of 96) had at least 1 late effect. Thirty-three percent of patients had a single late effect whereas 36% had >/= 2 late effects. Thirty percent of patients had a CTCv2 Grade 3 or 4 late effect. CONCLUSIONS: The current study represents an example of a successful multidisciplinary transition program in an ambulatory, adult setting for young adult survivors of childhood cancer. Late effects of cancer treatment are common in young adult survivors, with approximately 33% being moderate to severe. Further studies are needed to modify CTCv2 with the aim of developing a reliable and valid tool to assess late effects in long term survivors of childhood cancer. Copyright 2000 American Cancer Society.
Authors: Kevin C Oeffinger; Ann C Mertens; Melissa M Hudson; James G Gurney; Jacqueline Casillas; Hegang Chen; John Whitton; Mark Yeazel; Yutaka Yasui; Leslie L Robison Journal: Ann Fam Med Date: 2004 Jan-Feb Impact factor: 5.166
Authors: Christine Eiser; Kate Absolom; Diana Greenfield; John Snowden; Robert Coleman; Barry Hancock; Helena Davies Journal: J Cancer Surviv Date: 2007-03 Impact factor: 4.442
Authors: Gisela Michel; Renée L Mulder; Helena J H van der Pal; Roderick Skinner; Edit Bárdi; Morven C Brown; Janine Vetsch; Eva Frey; Rachael Windsor; Leontien C M Kremer; Gill Levitt Journal: J Cancer Surviv Date: 2019-08-08 Impact factor: 4.442
Authors: K Absolom; C Eiser; G Michel; S J Walters; B W Hancock; R E Coleman; J A Snowden; D M Greenfield Journal: Br J Cancer Date: 2009-07-28 Impact factor: 7.640
Authors: Wendy L Hobbie; Thomas Moshang; Claire A Carlson; Elizabeth Goldmuntz; Nancy Sacks; Samuel B Goldfarb; Stephan A Grupp; Jill P Ginsberg Journal: Pediatr Blood Cancer Date: 2008-11 Impact factor: 3.167
Authors: Rachel M A Linger; Alisa B Lee-Sherick; Deborah DeRyckere; Rebecca A Cohen; Kristen M Jacobsen; Amy McGranahan; Luis N Brandão; Amanda Winges; Kelly K Sawczyn; Xiayuan Liang; Amy K Keating; Aik Choon Tan; H Shelton Earp; Douglas K Graham Journal: Blood Date: 2013-07-16 Impact factor: 22.113